Please login to the form below

Not currently logged in
Email:
Password:

Sepracor signs EU marketing deal with GSK

Sepracor signs an agreement to market its sleep drug Lunivia with GSK in the EU

US-headquartered drug development company Sepracor has signed an agreement to market its sleep drug Lunivia (eszopiclone) in the EU with UK-based pharmaceutical company, GlaxoSmithKline (GSK).

Lunivia is currently under market review in the region, but has been commercially available in the US as Lunesta since 2005 to treat insomnia. Per the agreement, the drug will be marketed by GSK everywhere, except the US, Canada, Japan and Mexico.

Sepracor will receive an initial payment of USD 20m from GSK and is entitled to USD 155m in license and milestone payments, as well as double-digit royalties which would escalate upon increased product sales, says the firm.

In FY06, US product sales were about USD 566.8m, while the EU sedative hypnotic market was estimated to be worth about USD 500m in 2006.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics